You are here: Industry Insights > gene therapy

News List

The AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado worldpharmanews
April 02, 2019
AveXis further expanding AveXis' production capacity as it prepares to launch Zolgensma®...
Thermo Fisher shoulders into gene therapy manufacturing with $1.7B deal for Brammer firstwordpharma
March 25, 2019
With gene therapies becoming a hot growth area, CDMOs are figuring out how to get a bigger piece of the market. Thermo Fisher Scientific decided to buy its way in, agreeing to pay $1.7 billion to get viral vector producer Brammer Bio.
MilliporeSigma, GenScript to Accelerate Cell and Gene Therapy Industrialization in China contractpharma
March 20, 2019
MilliporeSigma has signed a collaboration agreement with China-based GenScript focusing on plasmid and viral vector manufacturing.
Biogen to buy gene therapy firm Nightstar Therapeutics for $800m pharmaceutical-technology
March 05, 2019
US-based biotechnology company Biogen has signed an agreement to acquire UK-based gene therapy firm Nightstar Therapeutics for a cash consideration of $800m.
Roche to acquire gene therapy specialist Spark Therapeutics for $4.8bn pharmaceutical-technology
February 26, 2019
Roche has signed a definitive merger agreement to acquire all outstanding shares of US-based gene therapy company Spark Therapeutics for $114.50 per share....
Can This Biotech Stock Redeem Its Sales Slip With A Strong Gene Therapy? firstwordpharma
February 24, 2019
Shares of BioMarin Pharmaceutical fell as much as 5.4 percent in response to disappointing fourth-quarter sales, Investor's Business Daily reported Friday.
ICER finds Novartis' gene therapy Zolgensma cost effective up to $900 000 based on commonly used threshold; Biogen, Ionis' Spinraza would need firstwordpharma
February 23, 2019
Using an alternate measure of life years (LY) gained at the threshold between $100 000 and $150 000, ICER found that Zolgensma would be cost-effective between $710 000 and $1.5 million.
Sapreme Technologies in a 6.8 M€ EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers b3cnewswire
February 21, 2019
Sapreme Technologies, a privately-held biotech company developing a technology platform to enable the cytosolic delivery of macromolecule therapeutics ....
Medicare coverage for CAR-T drugs on the horizon pharmaphorum
February 19, 2019
Medicare could soon cover CAR-T therapies under new proposals from the US’ Centers for Medicare & Medicaid Services (CMS), which aim to also gather real-world evidence to eventually inform expanded coverage.
Seven Trends of the Pharmaceutical Industry in 2019 (2) PharmaSources/Zhixing
February 18, 2019
Biosimilar, drug price increase and and more innovative therapies, What will be the trends of the medical world in 2019?

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page